CD155及其受体作为癌症治疗的点
Rossella Paolini1, Rosa Molfetta1
1Department of Molecular Medicine, Laboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Sapienza University of Rome, 00161 Rome, Italy.
CD155是一种促进瘤的分子,与免疫受体DNAM-1和TIGIT相互作用. 针对CD155或调节这些相互作用提供了潜在的癌症免疫疗法.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- CD155 (脊髓灰质炎病毒受体) 在瘤中过度表达,促进迁移和扩散.
- CD155作为淋巴细胞上DNAM-1 (激活) 和TIGIT (抑制) 受体的连接体.
- 紧密功能作为一个免疫检查点,抵消DNAM-1在晚期癌症的抗瘤监测.
研究的目的:
- 审查针对CD155及其相关免疫通路的治疗策略.
- 突出CD155在瘤进展中的复杂和争论的作用.
主要方法:
- 临床前和临床研究的文献综述.
- 对CD155与DNAM-1和TIGIT相互作用的分析.
- 评估治疗方法,包括直接向CD155和免疫检查点调节.
主要成果:
- 临床前研究表明,针对CD155或增强DNAM-1功能作为可行的治疗方法.
- 抗TIGIT抗体正在临床试验中,单独或结合治疗.
- CD155在瘤进展中的确切作用仍然是正在进行的研究和辩论的主题.
结论:
- 针对CD155/DNAM-1/TIGIT轴为癌症免疫治疗提供了有前途的途径.
- 需要进一步的研究,以充分阐明CD155的有争议的作用,并优化治疗策略.
更多相关视频
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
08:46A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Inhibition of Cdk Activity
